AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Cited by 641
Related Papers
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680
|Cancer Research|2006|277
Tuning a Three-Component Reaction For Trapping Kinase Substrate Complexes
|Journal of the American Chemical Society|2008|74